Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to Aotus Nonhuman Primates

Human Gene Therapy Clinical Development

Volumn 25, Issue 1, 2014, Pages 16-27

  Roth, Justin C ^a,b   Cassady, Kevin A ^a   Cody, James J ^a   Parker, Jackie N ^a   Price, Kathleen H ^a   Coleman, Jennifer M ^b   Peggins, James O ^c   Noker, Patricia E ^d   Powers, Nicholas W ^d   Grimes, Sheila D ^d   Carroll, Steven L ^e   Gillespie, G Yancey ^b,f,g   Whitley, Richard J ^a,b,f,h   Markert, James M ^a,b,f,g  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 12; M 032; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; AOTUS; ARTICLE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CLINICAL CHEMISTRY; CLINICAL OBSERVATION; COHORT ANALYSIS; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG SAFETY; EUTHANASIA; FEMALE; FIBROSIS; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; INJECTION SITE; LEUKOCYTE; MALE; MENINGITIS; MENINX DISORDER; MOTOR CORTEX; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE THERAPY; VIRUS ISOLATION;

ANIMALS; AOTIDAE; BRAIN NEOPLASMS; DRUG ADMINISTRATION ROUTES; FEMALE; GLIOMA; HERPESVIRUS 1, HUMAN; INFUSIONS, INTRAVENTRICULAR; INTERLEUKIN-12; MALE; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

EID: 84904422555     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2013.201     Document Type: Article

References (61)

1. Aghi, M., Chou, T.C., Suling, K., et al. (1999). Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 59, 3861-3865.
2. Albini, A., Brigati, C., Ventura, A., et al. (2009). Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J. Transl. Med. 7, 5.
3. Andreansky, S., He, B., Van Cott, J., et al. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5, 121-130.
4. Barahona, H., Melendez, L.V., Hunt, R.D., and Daniel, M.D. (1976). The owl monkey (Aotus trivirgatus) as an animal model for viral diseases and oncologic studies. Lab. Anim. Sci. 26, 1104-1112.
5. Cassady, K.A., and Parker, J.N. (2010). Herpesvirus vectors for therapy of brain tumors. Open. Virol. J 4, 103-108.
6. Chambers, R., Gillespie, G.Y., Soroceanu, L., et al. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA 92, 1411-1415.
7. Chase, M., Chung, R.Y., and Chiocca, E.A. (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. 16, 444-448.
8. Chou, J., Kern, E.R., Whitley, R.J., and Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
9. Farassati, F., Yang, A.D., and Lee, P.W. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745-750.
10. Feingold, K.R., and Grunfeld, C. (2010). The acute phase response inhibits reverse cholesterol transport. J. Lipid Res. 51, 682-684.
11. Goodwin, J.M., Schmitt, A.D., Mcginn, C.M., et al. (2012). Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model. Cancer Invest. 30, 243-250.
12. Gozalo, A., and Montoya, E. (1990). Mortality causes of owl monkeys (Aotus nancymae and Aotus vociferans) in captivity. J. Med. Primatol. 19, 69-72.
13. Guffey, M.B., Parker, J.N., Luckett, W.S., Jr., et al. (2007). Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 14, 45-56.
14. Han, Z.Q., Assenberg, M., Liu, B.L., et al. (2007). Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J. Gene Med. 9, 99-106.
15. Harrow, S., Papanastassiou, V., Harland, J., et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11, 1648-1658.
16. He, B., Gross, M., and Roizman, B. (1997). The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNAactivated protein kinase. Proc. Natl. Acad. Sci. USA 94, 843-848.
17. He, B., Gross, M., and Roizman, B. (1998). The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells. J. Biol. Chem. 273, 20737-20743.
18. Hellums, E.K., Markert, J.M., Parker, J.N., et al. (2005). Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol. 7, 213-224.
19. Hunter, W.D., Martuza, R.L., Feigenbaum, F., et al. (1999). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73, 6319-6326.
20. Katzin, D.S., Connor, J.D., Wilson, L.A., and Sexton, R.S. (1967). Experimental herpes simplex infection in the owl monkey. Proc. Soc. Exp. Biol. Med. 125, 391-398.
21. Kennedy, P.G., Adams, J.H., Graham, D.I., and Clements, G.B. (1988). A clinico-pathological study of herpes simplex encephalitis. Neuropathol. Appl. Neurobiol. 14, 395-415.
22. Khovidhunkit, W., Kim, M.S., Memon, R.A., et al. (2004). Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45, 1169-1196.
23. Koch, F., Stanzl, U., Jennewein, P., et al. (1996). High level IL- 12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184, 741-746.
24. Kramm, C.M., Chase, M., Herrlinger, U., et al. (1997). Therapeutic efficiency and safety of a second-generation replication- conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8, 2057-2068.
25. Liu, B.L., Robinson, M., Han, Z.Q., et al. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292-303.
26. Liu, T.C., Zhang, T., Fukuhara, H., et al. (2006). Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol. Ther. 14, 789-797.
27. Lowenstine, L.J. (2003). A primer of primate pathology: lesions and nonlesions. Toxicol. Pathol. 31 Suppl, 92-102.
28. Manetti, R., Gerosa, F., Giudizi, M.G., et al. (1994). Interleukin 12 induces stable priming for interferon gamma (IFNgamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J. Exp. Med. 179, 1273-1283.
29. Markert, J.M., Malick, A., Coen, D.M., and Martuza, R.L. (1993). Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32, 597-603.
30. Markert, J.M., Medlock, M.D., Rabkin, S.D., et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867-874.
31. Markert, J.M., Liechty, P.G., Wang, W., et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199-207.
32. Markert, J.M., Cody, J.J., Parker, J.N., et al. (2012). Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J. Virol. 86, 5304-5313.
33. Martuza, R.L., Malick, A., Markert, J.M., et al. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
34. Meignier, B., Martin, B., Whitley, R.J., and Roizman, B. (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162, 313-321.
35. Mineta, T., Rabkin, S.D., Yazaki, T., et al. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
36. Murphy, W.J., Welniak, L., Back, T., et al. (2003). Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8 + cell responses. J. Immunol. 170, 2727-2733.
37. Nakamori, M., Fu, X., Pettaway, C.A., and Zhang, X. (2004). Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 60, 53-60.
38. Nakamura, H., Mullen, J.T., Chandrasekhar, S., et al. (2001). Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5- fluorouracil. Cancer Res. 61, 5447-5452.
39. Papanastassiou, V., Rampling, R., Fraser, M., et al. (2002). The potential for efficacy of the modified (ICP 34.5( - )) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9, 398-406.
40. Parker, J.N., Gillespie, G.Y., Love, C.E., et al. (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA 97, 2208-2213.
41. Parker, J.N., Meleth, S., Hughes, K.B., et al. (2005). Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 12, 359-368.
42. Parker, J.N., Bauer, D.F., Cody, J.J., and Markert, J.M. (2009). Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6, 558-569.
43. Prabhakar, S., Brenner, G.J., Sung, B., et al. (2010). Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Ther. 17, 266-274.
44. Preusser, M., De Ribaupierre, S., Wohrer, A., et al. (2011). Current concepts and management of glioblastoma. Ann. Neurol. 70, 9-21.
45. Pyles, R.B., Warnick, R.E., Chalk, C.L., et al. (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8, 533-544.
46. Rampling, R., Cruickshank, G., Papanastassiou, V., et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859-866.
47. Sgadari, C., Angiolillo, A.L., and Tosato, G. (1996). Inhibition of angiogenesis by interleukin-12 is mediated by the interferoninducible protein 10. Blood 87, 3877-3882.
48. Shah, A.C., Benos, D., Gillespie, G.Y., and Markert, J.M. (2003). Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol. 65, 203-226.
49. Simpson, G.R., and Coffin, R.S. (2009). Construction and characterization of an oncolytic HSV vector containing a fusogenic glycoprotein and prodrug activation for enhanced local tumor control. Methods Mol. Biol. 542, 551-564.
50. Smith, K.D., Mezhir, J.J., Bickenbach, K., et al. (2006). Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma( 1)34.5 mutants of herpes simplex virus 1. J. Virol. 80, 1110-1120.
51. Stewart, V.A. (2003). Plasmodium vivax under the microscope: the Aotus model. Trends Parasitol. 19, 589-594.
52. Stupp, R., Hegi, M.E., Mason, W.P., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol. 10, 459-466.
53. Suzuki, S., Umezu, Y., Saijo, Y., et al. (1998). Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J. Exp. Med. 185, 223-226.
54. Takaoka, H., Takahashi, G., Ogawa, F., et al. (2011). A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma. Virol. J. 8, 294.
55. Todo, T., Feigenbaum, F., Rabkin, S.D., et al. (2000). Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in Aotus. Mol. Ther. 2, 588-595.
56. Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146.
57. Varghese, S., Newsome, J.T., Rabkin, S.D., et al. (2001). Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 12, 999-1010.
58. Voest, E.E., Kenyon, B.M., OReilly, M.S., et al. (1995). Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581-586.
59. Walker, J.D., Sehgal, I., and Kousoulas, K.G. (2011). Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J. Virol. 85, 7363-7371.
60. Wigginton, J.M., Lee, J.K., Wiltrout, T.A., et al. (2002). Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J. Immunol. 169, 4467-4474.
61. Yoo, J.Y., Haseley, A., Bratasz, A., et al. (2012). Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and Vstat120-expressing oncolytic virus. Mol. Ther. 20, 287-297.